Gastric / GEJ adenocarcinoma · line 1 · Bemarituzumab + mFOLFOX6 (FORTITUDE-101) — 1L FGFR2b-overexpressing HER2-non-positive gastric/GEJ

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-BEMARITUZUMAB-MFOLFOX6`

ID	`IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB`
Type	Indication
Status	reviewed 2026-05-07 \| pending_clinical_signoff
Diseases	`DIS-GASTRIC`
Sources	`SRC-ESMO-GASTRIC-2024` `SRC-FORTITUDE-101` `SRC-NCCN-GASTRIC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off (CHARTER §6.1: ≥2 reviewers for clinical content). Aggressive-track 1L for HER2-negative / MSI-stable / CLDN18.2-negative / FGFR2b-positive metastatic gastric / GEJ. Confidence: MODERATE — FORTITUDE-101 phase 3 primary analysis positive (mOS HR 0.61, p=0.005, ESMO 2025 LBA10) but attenuated at descriptive follow-up (HR 0.82) — practice-changing status disputed. SRC-FORTITUDE-101 upgraded from TODO-stub to canonical ESMO 2025 abstract-tier citation (GI-2 bemfill chunk 2026-05-07-1830); evidence_tier=2 because peer-reviewed full publication not yet indexed (paper_pending). REG-BEMARITUZUMAB-MFOLFOX6 created in same chunk (15 mg/kg IV q2w + mFOLFOX6 backbone). Engine routing to this indication will not fire until algorithm extension adds FGFR2b biomarker requirement (D1 algorithm chunk recommended). UA access: bemarituzumab not registered; named-patient / charitable / clinical-trial pathway only.

Used By

Algorithms

ALGO-GASTRIC-METASTATIC-1L - ALGO-GASTRIC-METASTATIC-1L

Sources

SRC-FORTITUDE-101 - Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing g...